News for Hercules Capital, Inc. (HTGC)

- Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne’s first planned commercial launch in early 2027 -

Summary Hercules Capital Inc (HTGC), a prominent specialty financing provider for venture, growth, and established stage companies, has announced its second qua

[url="]Hercules Capital, Inc.[/url] (NYSE: HTGC) (”œHercules” or the ”œCompany”), the largest and leading specialty financing provider to innovative vent

Hercules Capital (HTGC) to release Q2 2025 financial results on July 31, 2025. Conference call scheduled for 2:00 p.m. PT to discuss results. Hercule

On July 16, 2025, UBS analyst Vilas Abraham announced an increase in the price target for Hercules Capital (HTGC) from $18.50 to $19.00. This adjustment indicat

UBS analyst Doug Harter has adjusted the price target for Hercules Capital (HTGC), increasing it slightly from $18.50 to $19. Despite this upward revision, Hart

- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points -

Hercules Capital's focus on first-lien, floating rate debt in tech and life sciences offers stability, but growth will likely slow. Find out why HTGC is a Hold.

Summary Hercules Capital Inc (HTGC) has announced the successful closure of an upsized underwritten public offering, raising $350 million through the issuance o

[url="]Hercules Capital, Inc.[/url] (NYSE: HTGC) (”œHercules” or the ”œCompany”), today announced that it has closed an upsized underwritten public offer

Hercules Capital, Inc. (HTGC) completes $350 million upsized institutional notes offering. The notes bear a 6.000% interest rate, maturing in June 2030.

Hercules Capital is a holding due to premium valuation and rising concerns over portfolio quality. Read more to know why I see limited near-term upside with the HTGC stock.

Hercules Capital's strong Q1 performance and reliable dividends make it a standout for income investors. Learn more about HTGC stock here.

Hercules Capital focuses on technology sector, with portfolio value of $3.9 billion and low non-accrual ratio of 0.5%. Click to read why BXSL is a Strong Buy.

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the develop

On May 8, 2025, Nikos Theodosopoulos, a Director at Hercules Capital Inc, purchased 5,999 shares of the company. Following this transaction, the insider now hol

\nRobust investment income with a diversified portfolio in high-growth industries.Experienced a slight decrease in net investment income year-over-year.Challenge

Hercules Capital, Inc. (NYSE:HTGC) Q1 2025 Earnings Conference Call May 1, 2025 5:00 PM ETCompany ParticipantsMichael Hara - Senior Director, Investor...

While the top- and bottom-line numbers for Hercules Capital (HTGC) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.